You have 9 free searches left this month | for more free features.

Condition

Chronic HCV Infection (2)

Chronic Hepatics C Virus (HCV) Genotype 1 (1)

Cirrhosis (1)

Non-Cirrhotic (1)

Treatment naive (1)

Overall Status

Completed (3)

Sign in for free

Phase

phase 3 (2)

phase 2 (1)

Sponsor

Sunshine Lake Pharma Co., Ltd. (2)

Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd. (1)

Collaborator

Intervention

dag181 (3)

sof (2)

ribavirin (1)

tg-2349 (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

dag181

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Chronic Hepatics C Virus (HCV) Genotype 1, Non-Cirrhotic, Cirrhosis Trial in Beijing (TG-2349, DAG181, Ribavirin)

Completed

Chronic Hepatics C Virus (HCV) Genotype 1
+3 more

TG-2349
+2 more

Beijing, China

Beijing Tsinghua Changgung Hospital

Feb 2, 2021

Chronic HCV Infection Trial in China (SOF, DAG181)

Completed

Chronic HCV Infection

SOF
DAG181

Beijing, Beijing, China
+16 more

Mar 16, 2020

Chronic HCV Infection Trial in China (SOF, DAG181)

Completed

Chronic HCV Infection

SOF
DAG181

Beijing, Beijing, China
+34 more

Mar 16, 2020